Platelet APP Processing: Is It a Tool to Explore the Pathophysiology of Alzheimer's Disease? A Systematic Review

被引:6
作者
Carbone, Manuel Glauco [1 ]
Pagni, Giovanni [2 ]
Tagliarini, Claudia [2 ]
Marazziti, Donatella [3 ,4 ]
Pomara, Nunzio [5 ]
机构
[1] Univ Insubria, Dept Med & Surg, Div Psychiat, I-21100 Varese, Italy
[2] PISA Sch Expt & Clin Psychiat, I-56100 Pisa, Italy
[3] Univ Pisa, Dept Clin & Expt Med, Sect Psychiat, I-56100 Pisa, Italy
[4] St Camillus Int Univ Hlth & Med Sci, Dept Clin Psychol, I-00131 Rome, Italy
[5] Nathan S Kline Inst Psychiat Res, Geriatr Psychiat Dept, 140 Old Orangeburg Rd Orangeburg, New York, NY 10962 USA
来源
LIFE-BASEL | 2021年 / 11卷 / 08期
关键词
Alzheimer's disease; A beta cascade; platelet activation; APP processing; A beta amyloid; AMYLOID-PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; BLOOD-BRAIN-BARRIER; BETA-SECRETASE ACTIVITY; PHYSIOLOGICAL FUNCTIONS; GENE-EXPRESSION; BACE1; LEVELS; BIOMARKERS; ALPHA; DIAGNOSIS;
D O I
10.3390/life11080750
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The processing of the amyloid precursor protein (APP) is a critical event in the formation of amyloid plaques. Platelets contain most of the enzymatic machinery required for APP processing and correlates of intracerebral abnormalities have been demonstrated in platelets of patients with AD. The goal of the present paper was to analyze studies exploring platelet APP metabolism in Alzheimer's disease patients trying to assess potential reliable peripheral biomarkers, to offer new therapeutic solutions and to understand the pathophysiology of the AD. According to the PRISMA guidelines, we performed a systematic review through the PubMed database up to June 2020 with the search terms: "((((((APP) OR Amyloid Precursor Protein) OR AbetaPP) OR Beta Amyloid) OR Amyloid Beta) OR APP-processing) AND platelet". Thirty-two studies were included in this systematic review. The papers included are analytic observational studies, namely twenty-nine cross sectional studies and three longitudinal studies, specifically prospective cohort study. The studies converge in an almost unitary way in affirming that subjects with AD show changes in APP processing compared to healthy age-matched controls. However, the problem of the specificity and sensitivity of these biomarkers is still at issue and would deserve to be deepened in future studies.
引用
收藏
页数:19
相关论文
共 161 条
  • [31] β amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium:: usage of a novel blood brain barrier endothelial cell model system
    Davies, TA
    Long, HJ
    Eisenhauer, PB
    Hastey, R
    Cribbs, DH
    Fine, RE
    Simons, ER
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2000, 7 (03): : 153 - 165
  • [32] Activated Alzheimer disease platelets retain more beta amyloid precursor protein
    Davies, TA
    Long, HJ
    Sgro, K
    Rathbun, WH
    McMenamin, ME
    Seetoo, K
    Tibbles, H
    Billingslea, AM
    Fine, RE
    Fishman, JB
    Levesque, CA
    Smith, SJ
    Wells, JM
    Simons, ER
    [J]. NEUROBIOLOGY OF AGING, 1997, 18 (02) : 147 - 153
  • [33] Moderate and advanced Alzheimer's patients exhibit platelet activation differences
    Davies, TA
    Long, HJ
    Tibbles, HE
    Sgro, KR
    Wells, JM
    Rathbun, WH
    Seetoo, KF
    McMenamin, ME
    Smith, SJ
    Feldman, RG
    Levesque, CA
    Fine, RE
    Simons, ER
    [J]. NEUROBIOLOGY OF AGING, 1997, 18 (02) : 155 - 162
  • [34] NON-AGE RELATED DIFFERENCES IN THROMBIN RESPONSES BY PLATELETS FROM MALE-PATIENTS WITH ADVANCED ALZHEIMERS-DISEASE
    DAVIES, TA
    FINE, RE
    JOHNSON, RJ
    LEVESQUE, CA
    RATHBUN, WH
    SEETOO, KF
    SMITH, SJ
    STROHMEIER, G
    VOLICER, L
    DELVA, L
    SIMONS, ER
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 194 (01) : 537 - 543
  • [35] Loss-of-function presenilin mutations in Alzheimer disease - Talking Point on the role of presenilin mutations in Alzheimer disease
    De Strooper, Bart
    [J]. EMBO REPORTS, 2007, 8 (02) : 141 - 146
  • [36] Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimer's Disease
    Deane, R.
    Bell, R. D.
    Sagare, A.
    Zlokovic, B. V.
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (01) : 16 - 30
  • [37] RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
    Deane, R
    Yan, SD
    Submamaryan, RK
    LaRue, B
    Jovanovic, S
    Hogg, E
    Welch, D
    Manness, L
    Lin, C
    Yu, J
    Zhu, H
    Ghiso, J
    Frangione, B
    Stern, A
    Schmidt, AM
    Armstrong, DL
    Arnold, B
    Liliensiek, B
    Nawroth, P
    Hofman, F
    Kindy, M
    Stern, D
    Zlokovic, B
    [J]. NATURE MEDICINE, 2003, 9 (07) : 907 - 913
  • [38] Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study
    Decourt, Boris
    Walker, Aaron
    Gonzales, Amanda
    Malek-Ahmadi, Michael
    Liesback, Carolyn
    Davis, Kathryn J.
    Belden, Christine M.
    Jacobson, Sandra A.
    Sabbagh, Marwan N.
    [J]. PLATELETS, 2013, 24 (03) : 235 - 238
  • [39] Deeks J J, 2003, Health Technol Assess, V7, piii
  • [40] Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas
    den Haan, Jurre
    Morrema, Tjado H. J.
    Verbraak, Frank D.
    de Boer, Johannes F.
    Scheltens, Philip
    Rozemuller, Annemieke J.
    Bergen, Arthur A. B.
    Bouwman, Femke H.
    Hoozemans, Jeroen J.
    [J]. ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2018, 6 : 147